Navigation Links
Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
Date:7/23/2010

NORTHBROOK, Ill., July 23 /PRNewswire/ -- Horizon Pharma, Inc. announced today the results from the extended open label portion of The Circadian Administration of Prednisone in Rheumatoid Arthritis-1 (CAPRA-1) Phase 3 European registration study of LODOTRA®, a programmed release formulation of low-dose prednisone, which showed sustained improvement in reducing the duration of morning stiffness in patients with Rheumatoid Arthritis (RA) over a 12 month period.  The results were published in the July issue of the Annals of Rheumatic Diseases and were also recently presented at the European League Against Rheumatism (EULAR) Annual Congress.

"Symptoms of RA in patients, such as morning stiffness, show pronounced circadian rhythms with the highest severity in the early morning," said Frank Buttgereit, M.D., senior consultant and deputy head of the Department of Rheumatology and Clinical Immunology, Charite Hospital, Berlin and lead author of the study.  "The results from the open label portion of the CAPRA-1 study showed that the efficacy of glucocorticoid therapy can be sustained by synchronizing the drug release with the circadian rhythm of the underlying inflammation and resulting symptoms."

The CAPRA-1 study of LODOTRA evaluated 288 patients with active RA in a 12-week, randomized, double-blind, placebo-controlled trial comparing bedtime administration of LODOTRA with morning administration of immediate release (IR) prednisone at the same individual dose (an average dose of 6.7 mg).  Following the double-blind portion of the study, 249 patients continued on to an open label extension study for up to nine additional months, during which all patients received only an evening dose of LODOTRA.  Variables assessed included, among other things:  (i) r
'/>"/>

SOURCE Horizon Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
2. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
3. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
4. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
5. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
6. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
7. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
8. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
9. Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
10. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
11. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Surgeons at The Children,s Hospital of ... report the first successful use of a SynCardia temporary ... with failing Fontan circulation to bridge him to a ... old, the patient received a Fontan circulation procedure to ... "The Fontan operation is the final planned palliative operation ...
(Date:9/16/2014)... Va. , Sept. 16, 2014 ... Medical Directors Institute has simultaneously released the NAMCP ... NAMCP Medical Diagnostics Dossier Template © , which ... template formats for either medical devices or diagnostics ... aspects of each of these technology types (instead ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
Breaking Medicine Technology:13-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5
... The Netherlands, July 16 Neurofeedback - also,called EEG ... activity in order to,normalize Brain function and treat psychiatric ... 10 years, however the question,whether this treatment should be ... a study will be published in the scientific,journal ,EEG ...
... , , BOSTON and ... IIb multinational study(1) with edoxaban(2) - an investigational oral Factor ... atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer ... The analysis finds that bleeding associated with edoxaban is most ...
Cached Medicine Technology:New Research Shows: Neurofeedback is an 'Evidence-Based' Treatment for ADHD 2Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 2Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 3Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 4Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing 5
(Date:9/16/2014)... Today, Top10BestSEOHosting.com compares many ... USA and announces that HostMonster, Arvixe and ... Windows web hosting companies in the market. ... high quality WordPress hosting (including VPS and ... HostMonster provides outstanding customer support and a ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Not all ... they take care to make sure all their patients ... For some, this may include the newly-introduced online therapy. ... program which gives patients the opportunity to seek treatment ... can provide medical and clinical care at a distance. ...
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT consulting firm, ... high morale and collaborative culture in the ... Work For 2014.” Consulting magazine publishes the popular ... participating across all major industries, representing more than 350 ... firms were ranked in six categories - firm culture, ...
(Date:9/16/2014)... may one day be able to predict when and ... sexual functioning, thanks in part to new findings that ... American Society for Radiation Oncology,s 56th Annual Meeting on ... more than 17,000 surveys completed by men diagnosed with ... and sexual symptoms changed following each type of treatment, ...
(Date:9/16/2014)... September 16, 2014 Who:, The Pulmonary ... Medical Campus and Children’s Hospital Colorado are ... the country’s leading pulmonary hypertension association that works to find ... disease of the lungs that affects the functioning of the ... mean survivability is only 2.8 years. , What:, Colorado ...
Breaking Medicine News(10 mins):Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Millennium Treatment Group Now Offers Online Therapy 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 2Health News:Study identifies when and how much various prostate cancer treatments will impact urinary and sexual functioning 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... Insurance Convention Expected to Draw ... Protestors to San Francisco,Delgadillo to Discuss Legal Efforts to Crack Down ... and Unfair Business Acts and Practices" of Insurers, SAN ... of,protest against health insurance corporations, Los Angeles City Attorney,Rocky Delgadillo will ...
... the team that made the discovery, Professor Christopher Rowe ... and treatment presents medical practitioners with the best opportunity ... is at an experimental stage, this work places Australia ... Rowe says. , A 2004 Access Economics report calculated ...
... marks, get set go to lane 1? , ... connection between loud sounds and reaction time are reporting findings ... the upcoming Olympics. , Led by Dave Collins, professor ... hypothesized that the loud starter,s pistol at the Olympic Games ...
... Introduces ,The Insight, First ,Webisode, Featuring Guest, Hosts, Live Call-ins, ... ... Dealing With Change, BOCA RATON, Fla., ... Florida,s first weekly webisode -- a,transformational show called "The Insight" ...
... SAN CARLOS, Calif., June 18 Nuvelo, Inc.,(Nasdaq: ... the company,s chairman,and chief executive officer, will present at ... 2008, at 1:30 p.m. ET in New,York City., ... available online via,the Investor Relations portion of Nuvelo,s website ...
... ARAY ), a global leader in the field ... officer, Euan S.,Thomson, Ph.D., is scheduled to present at ... 10:15 a.m. EDT (7:15 a.m. PDT)., A live ... the,investor relations page of the Company,s Web site at, ...
Cached Medicine News:Health News:L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers 2Health News:L.A. City Attorney Rocky Delgadillo, Patient Activists to Unveil New Television Ad Targeting Health Insurers 3Health News:Advance towards early Alzheimer's diagnosis 2Health News:Sprinters closest to starter pistol have advantage over those farther away, says study 2Health News:A South Florida Premiere 2Health News:Accuray Incorporated's CEO to Speak at Jefferies Second Annual Healthcare Conference 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: